Continuous Lidocaine Infusion in Thyroid Surgery Using Intraoperative Neurophysiological Monitoring

Continuous Lidocaine Infusion in Thyroid Surgery Using Intraoperative Neurophysiological Monitoring

Thyroid surgery is a common procedure for the treatment of thyroid tumors, nodules and other related lesions. During this procedure, intraoperative neurophysiological monitoring is used to protect the recurrent laryngeal nerves. For the nerve monitor to work properly, a reduced muscle relaxant dosage is indicated. The main objectives of the anesthesiologist are maintaining deep sedation, analgesia and immobilization during surgery, as well as enhance post-operative recovery. Reduced muscle relaxant use during surgery poses the risk of inadequate immobilization during the operation, which may result in serious surgical complications. Intravenous bolus administration of fentanyl is currently the most popular method to maintain the depth of anesthesia during such operations. However, the side effects include intraoperative hypotension, bradycardia, and postoperative nausea and vomiting. The ultra-short acting remifentanil may be appropriate for inhibiting the bucking reflex during surgery, but the risk of opioid-induced hyperalgesia and opioid tolerance after surgery has been reported. In recent studies, intravenous lidocaine has been shown to increase the depth of anesthesia and provide analgesia, with no muscle relaxing effect.

The aim of this study is to examine the depth of anesthesia, surgical operating conditions, and the recovery profile with the use of a continuous lidocaine infusion.

1. Purpose of the Study:

   This study is a single-center clinical trial in Taiwan, targeting the enrollment of 150 participants. The primary goal is to evaluate the effects of lidocaine infusion in thyroid surgery and to analyze whether it differs from or offers advantages over conventional anesthetic methods. As with any treatment, risks are involved, and clinical trials are no exception. Please carefully consider your participation in this trial.

2. Current Status of the Investigational Products:

   • Lidocaine (Local Anesthetic):

   Lidocaine is a commonly used local anesthetic for injection, as well as a routine intravenous anesthetic induction drug in general anesthesia. It is also frequently used to treat arrhythmias. Large-scale data analyses confirm its high safety profile. Continuous infusion has been shown to enhance intraoperative sedation and postoperative pain relief.

   -Fentanyl and Remifentanil (Systemic Analgesics): Fentanyl and its ultra-short-acting variant, remifentanil, are the most commonly used opioid analgesics in surgical anesthesia.

3. Inclusion and Exclusion Criteria:

   Physicians or research staff at our hospital will discuss the necessary conditions for participation with you. Please provide honest information about your medical history.

   • Inclusion Criteria:

   Age: 20-75 years Diagnosed with thyroid nodules or tumors Recommended for surgical excision by general surgeons or otolaryngologists Use of recurrent laryngeal nerve monitoring during surgery

   • Exclusion Criteria:

   High anesthesia risk Liver or kidney function impairment Known allergies to anesthetic drugs used in the surgery (Sevoflurane, Propofol, Lidocaine, Remifentanil, Fentanyl)

4. Study Methods and Procedures:

   -Preoperative Assessment: If you decide to join and sign the consent form, a routine preoperative health examination will be conducted, including blood and urine tests, height and weight measurements, heart rate and blood pressure monitoring, ECG, and chest X-rays.

   -Study Design:

   Participants will be randomly divided into three groups of 50 individuals. All participants will receive general anesthesia and intraoperative recurrent laryngeal nerve monitoring. Each group will have a different anesthesia and pain management approach:

   • Group P (Intermittent Fentanyl Infusion): Maintained with volatile anesthetic gas (sevoflurane) and intermittent fentanyl infusion.
   • Group L (Continuous Lidocaine Infusion): Maintained with sevoflurane and continuous lidocaine infusion.
   • Group R (Continuous Remifentanil Infusion): Maintained with sevoflurane and continuous remifentanil infusion.

   All other anesthesia procedures will follow routine clinical practice.

   During the surgery, the following will be monitored and recorded:

   -Intraoperative vital signs (heart rate, blood pressure, oxygen saturation)

   -Anesthesia parameters (e.g., inhaled anesthetic concentration, bispectral index(BIS) monitoring, neuromuscular response)

   -Surgery quality, occurrences of bucking, and duration Dosages of fentanyl, remifentanil, and lidocaine used

   Postoperative evaluations include:

   -Surgical environment quality assessed by the surgeon

   -Recovery scores using the Aldrete scoring system

   -Pain scores (VAS, 1-10) in the recovery room

   • Analgesic use within 24 hours post-surgery
   • On the first postoperative day, a nurse will assess recovery, side effects (e.g., sore throat, nausea), and pain levels. Appropriate treatments will be provided if necessary.

5. Potential Side Effects and Management:

   Risks Associated with Investigational Products:

   • Common (<10%):

   Circulatory: Mild bradycardia, slight increase in blood pressure Central nervous system(CNS): Paresthesia, dizziness Gastrointestinal: Mild nausea or vomiting -Uncommon (<1%): Central nervous system(CNS): Central nervous toxicity (seizures, perioral numbness, tongue numbness, auditory hypersensitivity, confusion, mild headache, tinnitus, slurred speech) -Rare (<0.1%): Severe allergic reactions: Anaphylactic shock Central nervous system(CNS): Neuropathy, peripheral nerve damage, arachnoiditis, unconsciousness, tremors Cardiac: Cardiac arrest, arrhythmias Respiratory: Respiratory depression

   • Management of Serious Adverse Effects:

   Immediately stop the local anesthetic infusion and provide emergency treatment for systemic toxicity symptoms.

   For seizures, administer anticonvulsants (e.g., thiopental 100-500 mg IV, diazepam 5-10 mg IV). If needed, administer suxamethonium for muscle relaxation.

   For cardiovascular instability, administer ephedrine (5-10 mg IV), and repeat if necessary.

   If cardiac arrest occurs, initiate cardiopulmonary resuscitation.

   • Risks of Routine General Anesthesia:

   Propofol (IV anesthetic): May cause mild bradycardia; very rarely (<0.0014%) may result in severe bradycardia.

   Sevoflurane (inhaled anesthetic): May cause mild bradycardia, hypotension, or postoperative nausea/vomiting (30-40%).

   Fentanyl/Remifentanil: May cause mild bradycardia, hypotension, or postoperative nausea/vomiting (10-50%).

   -Management: For severe bradycardia or hypotension, appropriate medications will be administered.

   For nausea or vomiting, antiemetics will be provided as needed.

   -If any severe side effects occur, please: Contact the 24-hour emergency hotline. Seek medical attention at the nearest emergency room if necessary.

Inclusion Criteria:

• Age 20-75 years old
• Receiving open thyroid surgery
• Using intraoperative neurophysiological monitoring

Exclusion Criteria:

• Allergic to opioids or lidocaine.
• Unsuitable for prolonged lidocaine infusion due to impaired cardiac function or severe arrhythmias.
• Impaired renal function (eGFR < 30).
• Liver dysfunction (Child-Pugh score B/C).